Novo Nordisk raises 2026 profit outlook on Wegovy oral momentum despite pipeline impairment

Read the full summary

This story is older than our free news window. Create a free account to read Moatkeep's summary and the facts behind it — the headline, our numbers and the original sources stay open to everyone.